{"id":"https://openalex.org/W2951349998","doi":"https://doi.org/10.1002/hon.29_2630","title":"AN IMPROVED BENEFIT\u2010RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES","display_name":"AN IMPROVED BENEFIT\u2010RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES","publication_year":2019,"publication_date":"2019-06-01","ids":{"openalex":"https://openalex.org/W2951349998","doi":"https://doi.org/10.1002/hon.29_2630","mag":"2951349998"},"language":"en","primary_location":{"id":"doi:10.1002/hon.29_2630","doi":"https://doi.org/10.1002/hon.29_2630","is_oa":false,"landing_page_url":"https://doi.org/10.1002/hon.29_2630","pdf_url":null,"source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I.W. Flinn","raw_affiliation_strings":["Lymphoma Research, Sarah Cannon Research Institute, Nashville, TN, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Research, Sarah Cannon Research Institute, Nashville, TN, United States","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047631289","display_name":"Peter Hillmen","orcid":"https://orcid.org/0000-0001-5617-4403","observed_orcids":["https://orcid.org/0000-0001-5617-4403"]},"institutions":[{"id":"https://openalex.org/I2801331674","display_name":"St James's University Hospital","ror":"https://ror.org/013s89d74","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799390153","https://openalex.org/I2801331674"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P. Hillmen","raw_affiliation_strings":["Experimental Haematology, St James's University Hospital, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Haematology, St James's University Hospital, Leeds, United Kingdom","institution_ids":["https://openalex.org/I2801331674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039819830","display_name":"Marco Montillo","orcid":"https://orcid.org/0000-0003-0010-032X","observed_orcids":["https://orcid.org/0000-0003-0010-032X"]},"institutions":[{"id":"https://openalex.org/I4210094195","display_name":"Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda","ror":"https://ror.org/00htrxv69","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210094195"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"M. Montillo","raw_affiliation_strings":["Department of Haematology and Oncology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology and Oncology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy","institution_ids":["https://openalex.org/I4210094195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014405902","display_name":"Julio Delgado","orcid":"https://orcid.org/0000-0002-5157-4376","observed_orcids":["https://orcid.org/0000-0002-5157-4376"]},"institutions":[{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J. Delgado","raw_affiliation_strings":["Department of Hematology, Hospital Clinic, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Hospital Clinic, Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002467749","display_name":"Bryone Jean Kuss","orcid":"https://orcid.org/0000-0002-5811-1331","observed_orcids":["https://orcid.org/0000-0002-5811-1331"]},"institutions":[{"id":"https://openalex.org/I169541294","display_name":"Flinders University","ror":"https://ror.org/01kpzv902","country_code":"AU","type":"education","lineage":["https://openalex.org/I169541294"]},{"id":"https://openalex.org/I2802931750","display_name":"Flinders Medical Centre","ror":"https://ror.org/020aczd56","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2802931750"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"B.J. Kuss","raw_affiliation_strings":["Molecular Medicine and Pathology, Flinders Medical Centre - Flinders University, Bedford Park, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Medicine and Pathology, Flinders Medical Centre - Flinders University, Bedford Park, Australia","institution_ids":["https://openalex.org/I169541294","https://openalex.org/I2802931750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034517642","display_name":"Constantine Si Lun Tam","orcid":"https://orcid.org/0000-0002-9759-5017","observed_orcids":["https://orcid.org/0000-0002-9759-5017"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]},{"id":"https://openalex.org/I4210087110","display_name":"St Vincent's Hospital Melbourne","ror":"https://ror.org/001kjn539","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210087110","https://openalex.org/I4210098850"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"C.S. Tam","raw_affiliation_strings":["Division of Hematology and Oncology, Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne, Melbourne, Australia","institution_ids":["https://openalex.org/I165779595","https://openalex.org/I2800555584","https://openalex.org/I4210087110"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113865605","display_name":"Ulrich Jaeger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76134821","display_name":"Medical University of Vienna","ror":"https://ror.org/05n3x4p02","country_code":"AT","type":"education","lineage":["https://openalex.org/I76134821"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"U. J\u00e4ger","raw_affiliation_strings":["Division of Hematology and Hemostaseology, Department of Medicine, Medical University of Vienna, Wien, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Hemostaseology, Department of Medicine, Medical University of Vienna, Wien, Austria","institution_ids":["https://openalex.org/I76134821"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087770514","display_name":"Paolo Ghia","orcid":"https://orcid.org/0000-0003-3750-7342","observed_orcids":["https://orcid.org/0000-0003-3750-7342"]},"institutions":[{"id":"https://openalex.org/I154387261","display_name":"Vita-Salute San Raffaele University","ror":"https://ror.org/01gmqr298","country_code":"IT","type":"education","lineage":["https://openalex.org/I154387261"]},{"id":"https://openalex.org/I4210133214","display_name":"IRCCS Ospedale San Raffaele","ror":"https://ror.org/039zxt351","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210133214","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"P. Ghia","raw_affiliation_strings":["Universit\u00e0 Vita\u2010Salute San Raffaele IRCCS Istituto Scientifico San Raffaele  Milan Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e0 Vita\u2010Salute San Raffaele IRCCS Istituto Scientifico San Raffaele  Milan Italy","institution_ids":["https://openalex.org/I154387261","https://openalex.org/I4210133214"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019866348","display_name":"Stephan Stilgenbauer","orcid":"https://orcid.org/0000-0002-6830-9296","observed_orcids":["https://orcid.org/0000-0002-6830-9296"]},"institutions":[{"id":"https://openalex.org/I4210155144","display_name":"University Hospital Ulm","ror":"https://ror.org/05emabm63","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210155144"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"S. Stilgenbauer","raw_affiliation_strings":["Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany","institution_ids":["https://openalex.org/I4210155144"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006302059","display_name":"Stephanie Lustgarten","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154584","display_name":"Verastem (United States)","ror":"https://ror.org/0562yk913","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154584"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Lustgarten","raw_affiliation_strings":["Medical Affairs, Verastem Oncology, Needham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Verastem Oncology, Needham, MA, United States","institution_ids":["https://openalex.org/I4210154584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074838425","display_name":"David T. Weaver","orcid":"https://orcid.org/0000-0001-8398-3919","observed_orcids":["https://orcid.org/0000-0001-8398-3919"]},"institutions":[{"id":"https://openalex.org/I4210154584","display_name":"Verastem (United States)","ror":"https://ror.org/0562yk913","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154584"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D.T. Weaver","raw_affiliation_strings":["Medical Affairs, Verastem Oncology, Needham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Verastem Oncology, Needham, MA, United States","institution_ids":["https://openalex.org/I4210154584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065694446","display_name":"Hagop Youssoufian","orcid":"https://orcid.org/0009-0003-1673-8384","observed_orcids":["https://orcid.org/0009-0003-1673-8384"]},"institutions":[{"id":"https://openalex.org/I4210154584","display_name":"Verastem (United States)","ror":"https://ror.org/0562yk913","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154584"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Youssoufian","raw_affiliation_strings":["Medical Affairs, Verastem Oncology, Needham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Verastem Oncology, Needham, MA, United States","institution_ids":["https://openalex.org/I4210154584"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015131529","display_name":"Florence Cymbalista","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210129146","display_name":"H\u00f4pital Avicenne","ror":"https://ror.org/03n6vs369","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210129146"]},{"id":"https://openalex.org/I4405261462","display_name":"Laboratoire d'h\u00e9matologie","ror":"https://ror.org/05b9w4n89","country_code":"FR","type":"facility","lineage":["https://openalex.org/I204730241","https://openalex.org/I4210097159","https://openalex.org/I4405261462"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"F. Cymbalista","raw_affiliation_strings":["Laboratoire d'h\u00e9matologie H\u00f4pital Avicenne  Paris France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoire d'h\u00e9matologie H\u00f4pital Avicenne  Paris France","institution_ids":["https://openalex.org/I4210129146","https://openalex.org/I4405261462"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":17,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3500,"currency":"USD","value_usd":3500},"apc_paid":null,"fwci":0.185,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.52970201,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"37","issue":"S2","first_page":"213","last_page":"214"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duvelisib","display_name":"duvelisib","score":0.996999979019165},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9850000143051147},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/relapsed-refractory-disease","display_name":"relapsed/refractory disease","score":0.9319999814033508},{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":0.9169999957084656},{"id":"https://openalex.org/keywords/benefit-risk-profile","display_name":"benefit-risk profile","score":0.7940000295639038},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6850000023841858},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7149999737739563},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.984000027179718},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5820000171661377},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.4580000042915344},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.4090000092983246},{"id":"https://openalex.org/keywords/hemorrhagic-stroke","display_name":"hemorrhagic stroke","score":0.6579999923706055}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9211393594741821},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7101960778236389},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5881588459014893},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5192718505859375},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.5187692642211914},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4904143512248993},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.4847392737865448},{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.4391306936740875},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4307108223438263},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.4179290533065796},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.36320585012435913},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.35944998264312744},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.24539533257484436},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.18036267161369324},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/hon.29_2630","doi":"https://doi.org/10.1002/hon.29_2630","is_oa":false,"landing_page_url":"https://doi.org/10.1002/hon.29_2630","pdf_url":null,"source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2970760025","https://openalex.org/W2961546232","https://openalex.org/W2784823232","https://openalex.org/W2950306720","https://openalex.org/W2905375175","https://openalex.org/W2912098275","https://openalex.org/W3001171775","https://openalex.org/W4390273649","https://openalex.org/W2891876928","https://openalex.org/W3137375314"],"abstract_inverted_index":{"Introduction:":[0],"Despite":[1],"effective":[2],"frontline":[3],"therapies,":[4,323],"many":[5],"patients":[6],"(pts)":[7],"with":[8,192,263,291],"CLL":[9,42],"or":[10,40,43,84],"SLL":[11,44],"eventually":[12],"relapse":[13],"and":[14,54,180,200,213,243,284,307],"require":[15],"additional":[16,329],"therapies":[17,65,121,134],"to":[18,78,142,222,231,254,273,295],"control":[19],"their":[20],"disease.":[21],"Duvelisib":[22],"(DUV),":[23],"a":[24,106,232,266,303,324],"first-in-class":[25],"oral":[26,79],"dual":[27],"PI3K-\u03b4,\u03b3":[28],"inhibitor,":[29],"was":[30,101,135,140],"approved":[31],"by":[32,105],"the":[33,36,52,67,111,129,217,249],"FDA":[34],"for":[35,94],"treatment":[37],"of":[38,56,132,153,198,206,328],"relapsed":[39],"refractory":[41],"after":[45],"\u22652":[46,63,119,321],"prior":[47,64,120,133,322],"therapies.":[48,331],"Here":[49],"we":[50],"present":[51],"efficacy":[53,146],"safety":[55,305],"DUV":[57,80,139,157,229,264,300],"in":[58,66,151,196,204,256,275,315,326],"pts":[59,114,154,199,207,226,260,317],"who":[60,155,208,318],"had":[61,117,302,319],"received":[62,118,156,209,320],"phase":[68],"3":[69,136],"DUO":[70],"trial":[71],"(NCT02004522).":[72],"Methods:":[73],"Pts":[74],"were":[75,162,186,216,248,278,293],"randomized":[76],"1:1":[77],"25":[81],"mg":[82,89,93],"BID":[83],"IV":[85],"ofatumumab":[86],"(OFA)":[87],"300":[88],"once,":[90],"then":[91],"2000":[92],"12":[95],"doses":[96],"total.":[97],"The":[98,269],"primary":[99],"endpoint":[100],"PFS":[102],"as":[103],"assessed":[104],"blinded":[107],"IRC.":[108],"Results:":[109],"Of":[110],"319":[112],"total":[113],"randomized,":[115],"191":[116],"(93":[122],"DUV;":[123,210],"98":[124],"OFA).":[125],"In":[126],"this":[127],"population,":[128],"median":[130],"number":[131],"(range,":[137],"2-10).":[138],"superior":[141],"OFA":[143,292,314],"across":[144],"all":[145],"endpoints":[147],"(Table).":[148],"AEs":[149,185,220,290],"occurring":[150,195,203],">25%":[152],"(all":[158],"grade;":[159],"grade":[160],"\u22653)":[161],"diarrhea/colitis":[163,211,235],"(58%;":[164],"24%),":[165],"neutropenia":[166,214],"(40%;":[167],"38%),":[168],"pyrexia":[169],"(33%;":[170],"2%),":[171],"upper":[172],"respiratory":[173],"infection":[174],"(30%;":[175],"0%),":[176],"pneumonia":[177,239,286],"(29%;":[178],"22%),":[179],"fatigue":[181],"(26%;":[182],"3%).":[183],"Many":[184],"successfully":[187],"managed":[188],"through":[189],"dose":[190,193,201,223],"modifications,":[191],"reductions":[194],"28%":[197],"interruptions":[202],"74%":[205],"(10%)":[212],"(5%)":[215],"most":[218],"common":[219],"leading":[221,253],"reduction.":[224],"22":[225],"(23%)":[227],"discontinued":[228],"due":[230],"related":[233],"AE;":[234],"(n":[236,240,245,281,287],"=":[237,241,246,282,288],"8),":[238],"3),":[242],"pneumonitis":[244],"2)":[247,283],"only":[250,270],"treatment-related":[251],"events":[252,272],"discontinuation":[255],">1":[257,276],"pt.":[258],"11":[259],"(12%)":[261],"treated":[262],"experienced":[265],"fatal":[267,271],"AE.":[268],"occur":[274],"pt":[277],"hemorrhagic":[279],"stroke":[280],"staphylococcal":[285],"2).":[289],"similar":[294],"those":[296],"previously":[297],"reported.":[298],"Conclusions:":[299],"monotherapy":[301],"manageable":[304],"profile":[306],"demonstrated":[308],"significantly":[309],"improved":[310],"clinical":[311],"outcomes":[312],"over":[313],"CLL/SLL":[316],"population":[325],"need":[327],"targeted":[330],"Keywords:":[332],"chronic":[333],"lymphocytic":[334],"leukemia":[335],"(CLL);":[336],"Duvelisib;":[337],"PI3K/AKT/mTOR.":[338],"Disclosures:":[339],"Flinn,":[340],"I:":[341],"Consultant":[342,408,449,467,481,521,567,596,669,695],"Advisory":[343,409,450,468,482,522,568,597,670,696],"Role:":[344,410,451,469,483,523,569,598,671,697],"Abbvie,":[345,383,511,526,534,557],"Seattle":[346],"Genetics,":[347],"TG":[348,379,429,444],"Therapeutics,":[349,371,380,382,388,401,403,430,445],"Verastem":[350,395,452,656,660,667,677,687,691],"Oncology":[351],";":[352],"Research":[353,432,459,515,551,584,615,705],"Funding:":[354,433,460,516,552,585,616,706],"Acerta":[355,412,434],"Pharma,":[356,373,413,423,435,440],"Agios,":[357],"Calithera":[358],"Biosciences,":[359],"Celgene,":[360,417,525,533,559,573,581],"Constellation":[361],"Pharmaceuticals,":[362,368,377,428,541,561],"Genentech,":[363,418,438],"Gilead":[364,397,419,529,537,554,606,624,642],"Sciences,":[365,398,420,538,555],"Incyte,":[366],"Infinity":[367,560],"Janssen,":[369,421,457,463,486,494,502,574,582,587,703,711],"Karyopharm":[370],"Kite":[372],"Novartis,":[374,512,528,536,553],"Pharmacyclics,":[375,425,441],"Portola":[376],"Roche,":[378,426,484,492,503,527,535,556,702,710],"Trillium":[381],"ArQule,":[384],"BeiGene,":[385,572,580],"Curis,":[386],"Forma":[387],"Forty":[389],"Seven,":[390],"Merck,":[391,424],"Pfizer,":[392],"Takeda,":[393,488,496,548,563],"Teva,":[394],"Oncology,":[396,443,678],"AstraZeneca,":[399,571,579],"Juno":[400],"Unum":[402],"MorphoSys,":[404],"AG.":[405],"Davids,":[406],"M:":[407,466],"AbbVie,":[411,455,461,485,493,504,570,578,586],"Adaptive":[414],"Biotechnologies,":[415],"Astra-Zeneca,":[416],"MEI":[422,439],"Syros":[427],"Verastem;":[431],"Bristol-Myers":[436,549],"Squibb,":[437],"Surface":[442],"Verastem.":[446],"Hillmen,":[447],"P:":[448,566],"Oncology;":[453,657,668,688],"Honoraria:":[454,475,491,509,531,577,699],"Gilead,":[456,462,489,497,501,505,575,588,701],"Roche;":[458,613,631,649],"Roche.":[464],"Montillo,":[465],"ABBVIE,":[470,476],"JANSSEN;":[471],"GILEAD,":[472],"ASTRA":[473],"ZENECA;":[474],"JANSSEN,":[477],"GILEAD.":[478],"Kuss,":[479],"B:":[480],"Mundipharma,":[487,495,546],"Merck;":[490,498],"Other":[499,591,633,708],"Remuneration:":[500,592,634,709],"Janssen.":[506],"Tam,":[507],"C:":[508],"Janssen-Cilag,":[510,517,545,562],"Beigene,":[513],"Pharmacyclics;":[514,612,630,648],"Abbvie.":[518],"J\u00e4ger,":[519],"U:":[520],"Amgen,":[524,532],"Sciences;":[530,607,625,643],"AOP":[539],"Orphan":[540],"Bioverativ,":[542,558],"Emergent":[543],"BioSolutions,":[544],"Sandoz,":[547],"Squibb;":[550],"MSD.":[564],"Ghia,":[565],"Sunesis;":[576,704,707],"Gilead;":[583],"Sunesis,":[589],"Novartis;":[590,611,629,647],"Gilead.":[593,713],"Stilgenbauer,":[594],"S:":[595,652],"AbbVie;":[599],"Amgen;":[600,618,636],"Boehringer":[601,619,637],"Ingelheim;":[602,620,638],"Celgene;":[603,621,639],"Genentech;":[604,622,640],"Genzyme;":[605,623,641],"GlaxoSmithKline;":[608,626,644],"Janssen;":[609,627,645],"Mundipharma;":[610,628,646],"Sanofi;":[614,632],"Abbvie;":[617,635,698],"Sanofi.":[650],"Lustgarten,":[651],"Employment":[653,664,684],"Leadership":[654,665,685],"Position:":[655,666,686],"Stock":[658,675,689],"Ownership:":[659,676,690],"Oncology.":[661,692],"Weaver,":[662],"D:":[663],"FemtoDx,":[672,679],"Nanogen":[673,680],"Therapeutics;":[674],"Therapeutics.":[681],"Youssoufian,":[682],"H:":[683],"Cymbalista,":[693],"F:":[694],"Abbive,":[700],"Abbvie":[712]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-06-27T00:00:00"}